Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.
Emma J Mickley
Advertisement
Emma J Mickley, PhD, vice-president, corporate business development, Aesica Pharmaceuticals
Articles by Emma J Mickley
Advertisement
Latest Updated Articles
Fit for the Lung?Published: September 2nd 2014 | Updated:
Advertisement
Advertisement
